Sixteen patients with recurrent high-grade glioma who were treated by domestic magnetic resonance-guided laser interstitial thermotherapy (MRgLITT) in the Neurosurgery Department of Xuanwu Hospital of Capital Medical University from 1st January 2021 to 31st December 2021 were prospectively included, with 11 males and 5 females, and aged 27-74 (50±16) years. The duration of surgery, the rate of ablation after surgery, and perioperative complications were assessed. The patients were followed up every 3 months to assess survival and progression. A total of 5 WHO grade Ⅲ patients and 11 WHO grade Ⅳ patients were included. The operation time was 144 (109, 176) min, 28 targeted lesions were detected, and the ablation rate [M (Q1, Q3)] was 91.0% (87.4%, 93.3%). After surgery, 2 patients (2/16) had decreased limb muscle strength, and no perioperative death or other serious complications occurred. The median time to a complete response was 12 (5, 14) months in WHO Grade Ⅲ patients, and one died 12 months after surgery, while the median time to a complete response was 3 (1, 8) months in 11 WHO Grade Ⅳ patients, with a total of 8 deaths at the last follow-up. Therefore, domestic MRgLITT has certain efficacy and safety in the treatment of recurrent high-grade glioma, providing a new option for patients with recurrent glioma.
前瞻性纳入2021年1月1日至12月31日首都医科大学宣武医院神经外科使用国产磁共振引导激光间质热疗（MRgLITT）治疗的复发高级别胶质瘤患者16例，男11例，女5例，年龄27~74（50±16）岁。评估手术时间、手术后病灶消融率、围手术期并发症，并且每3个月进行随访，评估患者是否生存以及病情进展情况。共纳入5例WHO Ⅲ级患者和11例WHO Ⅳ级患者，手术时间［M（Q1，Q3）］为144（109，176）min，病灶靶点共28个，病灶消融率91.0%（87.4%，93.3%）。术后2例（2/16）患者出现肢体肌力下降，无围手术期死亡和其他严重并发症。WHO Ⅲ级患者完全缓解期为12（5，14）个月，其中1例在术后12个月死亡。11例WHO Ⅳ级的患者完全缓解期为3（1，8）个月，截至末次随访，共有8例死亡。MRgLITT在复发高级别胶质瘤的治疗中具有一定的有效性和安全性，为复发胶质瘤患者提供了新的选择。.